PE20230108A1 - Variantes de anticuerpos caninos - Google Patents

Variantes de anticuerpos caninos

Info

Publication number
PE20230108A1
PE20230108A1 PE2022002420A PE2022002420A PE20230108A1 PE 20230108 A1 PE20230108 A1 PE 20230108A1 PE 2022002420 A PE2022002420 A PE 2022002420A PE 2022002420 A PE2022002420 A PE 2022002420A PE 20230108 A1 PE20230108 A1 PE 20230108A1
Authority
PE
Peru
Prior art keywords
igg
canine
variants
substitution
modified
Prior art date
Application number
PE2022002420A
Other languages
English (en)
Inventor
Lisa Marie Bergeron
Henry Luis Campos
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of PE20230108A1 publication Critical patent/PE20230108A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/524CH2 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/526CH3 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72Increased effector function due to an Fc-modification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

REFERIDO A VARIANTES DE ANTICUERPOS CANINOS, ESPECIFICAMENTE A UNA IgG MODIFICADA QUE COMPRENDE: UN DOMINIO CONSTANTE DE LA IgG CANINA QUE COMPRENDE AL MENOS UNA SUSTITUCION DE AMINOACIDOS CON RESPECTO A UN DOMINIO CONSTANTE DE LA IgG CANINA DE TIPO SALVAJE, EN DONDE DICHA SUSTITUCION ES UNA SUSTITUCION DE ASPARAGINA EN LA POSICION 434 CON HISTIDINA (N434H); DICHA IgG MODIFICADA TIENE UNA MAYOR AFINIDAD PARA FcRn QUE LA IgG QUE TIENE EL DOMINIO CONSTANTE DE LA IgG CANINA DE TIPO SALVAJE. TAMBIEN SE REFIERE A UN POLIPEPTIDO, UNA MOLECULA DE INMUNOGLOBULINA COMO ANTI-IL31 O ANTI-NGF, Y A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE LA IgG MODIFICADA.
PE2022002420A 2020-04-17 2021-04-16 Variantes de anticuerpos caninos PE20230108A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063011453P 2020-04-17 2020-04-17
PCT/US2021/027836 WO2021212081A1 (en) 2020-04-17 2021-04-16 Canine antibody variants

Publications (1)

Publication Number Publication Date
PE20230108A1 true PE20230108A1 (es) 2023-01-25

Family

ID=75888187

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022002420A PE20230108A1 (es) 2020-04-17 2021-04-16 Variantes de anticuerpos caninos

Country Status (16)

Country Link
US (1) US20230242635A1 (es)
EP (1) EP4136106A1 (es)
JP (1) JP2023522029A (es)
KR (1) KR20230005156A (es)
CN (1) CN115996949A (es)
AU (1) AU2021256056A1 (es)
BR (1) BR112022020944A2 (es)
CA (1) CA3175921A1 (es)
CL (2) CL2022002857A1 (es)
CO (1) CO2022014695A2 (es)
EC (1) ECSP22080846A (es)
IL (1) IL297287A (es)
MX (1) MX2022012866A (es)
PE (1) PE20230108A1 (es)
TW (1) TW202204403A (es)
WO (1) WO2021212081A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
MX2021008144A (es) 2019-01-03 2021-10-13 Invetx Inc Composiciones para aumentar la media vida de un agente terapeutico en caninos y metodos de uso.
BR112022022922A2 (pt) 2020-05-11 2023-01-17 Invetx Inc Composições para aumentar a meia-vida de um agente terapêutico em caninos e métodos de uso
MX2023000500A (es) 2020-07-10 2023-04-12 Invetx Inc Composiciones para aumentar la semivida de un agente terapeutico en felinos y modos de uso.
CN116438196A (zh) * 2020-09-28 2023-07-14 硕腾服务有限责任公司 犬抗体变体
WO2023250284A2 (en) * 2022-06-21 2023-12-28 Zoetis Services Llc Canine antibody mutants

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
EP1778728A2 (en) 2004-08-19 2007-05-02 Genentech, Inc. Polypeptide variants with altered effector function
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
DK2325207T3 (en) 2004-11-12 2017-06-06 Xencor Inc Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
AU2011291462A1 (en) 2010-08-19 2013-03-14 Zoetis Belgium S.A. Anti-NGF antibodies and their use
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
KR20230079499A (ko) * 2016-08-05 2023-06-07 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
WO2018073185A1 (en) * 2016-10-17 2018-04-26 Vetoquinol Sa Modified antibody constant region
MX2021004313A (es) * 2018-10-18 2021-05-27 Kindred Biosciences Inc Variantes de fc con union alterada al receptor de fc neonatal (fcrn) para uso veterinario.
MX2021008144A (es) * 2019-01-03 2021-10-13 Invetx Inc Composiciones para aumentar la media vida de un agente terapeutico en caninos y metodos de uso.
US20220169740A1 (en) * 2019-03-20 2022-06-02 Kindred Biosciences, Inc. NGF Antagonists for Medical Use

Also Published As

Publication number Publication date
ECSP22080846A (es) 2023-02-28
JP2023522029A (ja) 2023-05-26
CN115996949A (zh) 2023-04-21
WO2021212081A1 (en) 2021-10-21
CO2022014695A2 (es) 2022-10-21
AU2021256056A1 (en) 2022-10-20
CL2022002857A1 (es) 2023-06-02
IL297287A (en) 2022-12-01
MX2022012866A (es) 2022-11-08
KR20230005156A (ko) 2023-01-09
CA3175921A1 (en) 2021-10-21
TW202204403A (zh) 2022-02-01
BR112022020944A2 (pt) 2022-12-27
US20230242635A1 (en) 2023-08-03
CL2023003377A1 (es) 2024-04-19
EP4136106A1 (en) 2023-02-22

Similar Documents

Publication Publication Date Title
PE20230108A1 (es) Variantes de anticuerpos caninos
PE20230348A1 (es) Variantes de anticuerpos felinos
BR112016016416A2 (pt) VARIANTES DE REGIÕES-"Fc" COM 'FcRn' MODIFICADAS E PROPRIEDADES DE LIGAÇÃO DE PROTEÍNA "A" MANTIDAS
BR112016016411A2 (pt) VARIANTES DE REGIÕES-"Fc" COM PROPRIEDADES DE LIGAÇÃO DE "FcRn" MODIFICADAS
EA202090247A1 (ru) Антитела против cd166 и их применения
CL2018000238A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
ES2676023T3 (es) Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso
EA201991701A1 (ru) Состав на основе моноклонального антитела к rsv
BR112017006591A2 (pt) polipeptídeo heterodimérico, formulação farmacêutica e uso de um polipeptídeo heterodimérico
BR112016020065A2 (pt) sítios específicos para modificar anticorpos para fazer imunoconjugados
BR112018000477A2 (pt) proteína de ligação de imunoglobulina não natural, composição, uso da proteína de ligação de ig não natural, método de purificação de afinidade de imunoglobulinas, método de geração de uma proteína de ligação de imunoglobulina não natural, molécula de ácido nucleico, vetor, célula hospedeira ou um hospedeiro não humano, e método para a produção de uma proteína de ligação de imunoglobulina não natural
CU20180136A7 (es) Anticuerpos monoclonales aislados que compiten por la union a tau con el anticuerpo 16g7
BR112017003194B8 (pt) Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente a lag3 humano, composição, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo e da composição
NZ724904A (en) Hybrid immunoglobulin containing non-peptidyl linkage
BR112016014810A2 (pt) Antagonistas de fcrn e métodos de uso
PE20131141A1 (es) Anticuerpo monoclonal
AR074427A1 (es) Composiciones estables de anticuerpos y metodos para estabilizarlas
EA201291181A1 (ru) Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
PE20211214A1 (es) Variantes de pertuzumab y su evaluacion
EA202192146A1 (ru) Антитела к клаудину 6 и их применение
EA201991464A1 (ru) АНТИТЕЛО К α-СИНУКЛЕИНУ И ЕГО ПРИМЕНЕНИЕ
EA202190264A1 (ru) КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn
BR112021020204A2 (pt) Método para purificar anticorpo com região fc modificada
EA202092508A1 (ru) Составы на основе антител к pd-l1 человека
BR112022022922A2 (pt) Composições para aumentar a meia-vida de um agente terapêutico em caninos e métodos de uso